Table 1—

Efficacy ofi.v. topotecan (1.5 mg·m-2·day-1, on days 1–5) in second-line small cell lung cancer

First author [ref.]Subjects nCRPROR %SD %Survival weeks#
Eckhardt 9
 Refractory3812.64520.4
 Sensitive36+3419.43626.6
 Total7410.840.5NR
von Pawel 10
 Refractory4112.4NR16.3
 Sensitive57+1714.0NR25.7
 Total989.22721.6
Ardizzoni 11
 Refractory47126.44018.8
 Sensitive45+61137.83127.6
 Total9221.735.921.6
  • CR: complete response; PR: partial response; OR: odds ratio; SD: stable disease; NR: not reported. #: median. : patients who failed to respond or progressed within 90 days of first-line therapy were termed refractory; +: patients who relapsed after 90 days after first-line therapy were termed sensitive.